MBX-1416 by MBX Biosciences Inc for Hypoglycemia: Likelihood of Approval

Emer­gent BioSo­lu­tions is sell­ing off a Bal­ti­more man­u­fac­tur­ing site for $30 mil­lion to Bo­ra Phar­ma­ceu­ti­cals. “The de­ci­sion to sell our Cam­den man­u­fac­tur­ing fa­cil­i­ty is aligned

The FDA on Tues­day cleared Mer­ck’s pul­monary ar­te­r­i­al hy­per­ten­sion treat­ment, which could quick­ly be­come a block­buster for the New Jer­sey phar­ma gi­ant. Mer­ck will mar­ket